Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Drug Approvals Reached Record-High In 2017
Before patients can take prescriptions to a pharmacy and get their medications, FDA has to approve drugs first.
Sanofi, Regeneron beef up investment in immunotherapies
Sanofi and Regeneron are boosting their investment in development programmes for the PD-1 antibody cemiplimab in oncology and dupilumab in Type 2 (tissue specific) allergic diseases.
Pfizer, Arvinas to collaborate on PROTACs
Arvinas and Pfizer have signed a research collaboration and license agreement relating to the discovery and development of protein degradation drug candidates.
Shire cuts 2020 revenue target, prepares for spin-off of ADHD drugs
Shire announced on Monday it would drop its revenue target of $20 billion by 2020, citing increased competition from generics and rival drug companies.
Celgene to buy Impact Biomedicines for up to $7 billion
U.
Lupin launches generic Ancobon
Lupin has added to its generics lineup with its version of Valeant Pharmaceuticals’ Ancobon (flucytosine) capsules.
Takeda to acquire TiGenix in $630 million deal
Japan’s largest drugmaker Takeda Pharmaceutical (TYO.
Leading Pharma gets $40 million infusion for growth
Generic maker Leading Pharma recently completed a financing transaction for $40 million of growth capital.
Alnylam and Sanofi Enter into Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance
CAMBRIDGE, Mass.
Atlas Venture Launches Generation Bio
Cambridge, Mass.
ChemDiv, DZNE and Torrey Pines Investment Launch Inflammasome Discovery Program of Translational Collaboration on Neurodegeneration
SAN DIEGO and BONN, Jan.
Pfizer ends research for new Alzheimer's, Parkinson's drugs
NEW YORK (Reuters) - Pfizer Inc (PFE.
504
505
506
507
508
509
510
511
512
